Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2169232-81-7] Magrolimab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P99029 |
| Brand: | MCE |
| CAS: | 2169232-81-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Magrolimab] |
For research use only. We do not sell to patients.
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03869190 | Hoffmann-La Roche|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas |
Urothelial Carcinoma|Bladder Cancer
|
June 1, 2019 | Phase 1|Phase 2 |
| NCT03922477 | Hoffmann-La Roche |
Acute Myeloid Leukemia
|
October 8, 2019 | Phase 1 |
| NCT03248479 | Gilead Sciences |
Hematological Malignancies
|
September 8, 2017 | Phase 1 |
| NCT03527147 | Acerta Pharma BV|AstraZeneca |
NHL|DLBCL|Non-hodgkin´s Lymphoma|Diffuse Large B Cell Lymphoma
|
June 19, 2018 | Phase 1 |
| NCT04854499 | Gilead Sciences |
Head and Neck Squamous Cell Carcinoma
|
September 7, 2021 | Phase 2 |
| NCT04827576 | Gilead Sciences |
Solid Tumor
|
October 1, 2021 | Phase 2 |
| NCT02678338 | Gilead Sciences|California Institute for Regenerative Medicine (CIRM) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
November 2015 | Phase 1 |
| NCT02953782 | Gilead Sciences|California Institute for Regenerative Medicine (CIRM) |
Solid Tumor|Colorectal Cancer
|
November 2, 2016 | Phase 1|Phase 2 |
| NCT05079230 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 7, 2022 | Phase 3 |
| NCT04541017 | National Cancer Institute (NCI) |
Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Sezary Syndrome|Refractory Mycosis Fungoides|Refractory Mycosis Fungoides and Sezary Syndrome|Refractory Sezary Syndrome|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
|
December 24, 2020 | Phase 1|Phase 2 |
| NCT04313881 | Gilead Sciences |
Myelodysplastic Syndromes
|
September 9, 2020 | Phase 3 |
| NCT02216409 | Gilead Sciences |
Solid Tumor
|
August 2014 | Phase 1 |
| NCT05330429 | Gilead Sciences |
Metastatic Colorectal Cancer
|
July 8, 2022 | Phase 2 |
| NCT04788043 | Stanford University|Merck Sharp & Dohme LLC |
Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Relapsed Classical Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma
|
June 21, 2022 | Phase 2 |
| NCT04751383 | National Cancer Institute (NCI) |
High Risk Neuroblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Neuroblastoma|Resectable Osteosarcoma
|
April 16, 2021 | Phase 1 |
| NCT02953509 | Gilead Sciences|The Leukemia and Lymphoma Society |
Non Hodgkin Lymphoma
|
November 21, 2016 | Phase 1|Phase 2 |
| NCT04599634 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Lymphoma|B-Cell Lymphoma
|
December 16, 2021 | Phase 1 |
| NCT04778410 | Gilead Sciences |
Myeloid Malignancies
|
June 28, 2021 | Phase 2 |
| NCT03558139 | Gilead Sciences|Merck KGaA, Darmstadt, Germany |
Ovarian Cancer
|
May 23, 2018 | Phase 1 |
| NCT04778397 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2021 | Phase 3 |
| NCT05169944 | University of California, San Francisco|Gilead Sciences |
Brain Cancer|Malignant Brain Tumor|Recurrent Brain Tumor|Progressive Malignant Brain Tumor|Brain Tumor, Pediatric|Brain Tumor Adult
|
April 22, 2022 | Phase 1 |
| NCT05367401 | Novartis Pharmaceuticals|Novartis |
Myelodysplastic Syndromes|Acute Myeloid Leukemia
|
December 20, 2024 | Phase 1|Phase 2 |
| NCT04958785 | Gilead Sciences |
Triple-Negative Breast Cancer
|
December 14, 2021 | Phase 2 |
| NCT04435691 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
July 28, 2020 | Phase 1|Phase 2 |
| NCT04892446 | Gilead Sciences |
Multiple Myeloma
|
November 9, 2021 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.